Skip to Content

ACTOplus met Approval History

FDA Approved: Yes (First approved August 29, 2005)
Brand name: ACTOplus met
Generic name: pioglitazone and metformin
Dosage form: Tablets
Company: Takeda Pharmaceuticals
Treatment for: Diabetes, Type 2

ACTOplus met (pioglitazone and metformin) is a combination antihyperglycemic medication used in the management of type 2 diabetes.

Development History and FDA Approval Process for ACTOplus met

DateArticle
May 13, 2009Approval FDA Approves ACTOplus met XR (pioglitazone HCl and metformin HCl extended-release) Tablets for the Treatment of Type 2 Diabetes
Aug 29, 2005Approval ACTOplus met Takeda Pharmaceuticals - Treatment for Type 2 Diabetes
Oct 29, 2004Takeda Submits New Drug Application for Combination Type 2 Diabetes Medication, Actoplus Met (pioglitazone HCl and metformin HCl)

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide